Evidence map›Paper›PMID 41225020›Full record

ArticleScientific reports2025

A new, patient-friendly, needleless methotrexate administration method using the pyro-drive jet injector in rats.

Mikiko Shimizu, Tsuyoshi Shiga, Masayuki Hashiguchi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mikiko ShimizuDepartment of Pharmaceutics and Pharmacometrics, Shujitsu University School of Pharmacy, Okayama, Japan.
Tsuyoshi ShigaDepartment of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Masayuki HashiguchiDepartment of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan. hashiguchi-ms@jikei.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate (MTX) is the anchor first-line drug for the treatment of rheumatoid arthritis (RA) in the RA guidelines of the ACR, JCR and EULAR. In the guidelines, MTX is primarily administered orally as low-dose pulse therapy. However, oral MTX therapy has a large interindividual variation of drug efficacy/adverse drug reactions due to bioavailability (BA) differences and it is often associated with gastrointestinal disturbances, making some patients unable to continue oral MTX therapy. MTX subcutaneous (SC) administration involves pain at the injection site and there are regulatory issues in disposal related to medical waste. The pyro-drive jet injector (PJI) is an innovative, needle-free drug delivery system that enables targeted delivery of drugs. This study investigated the pharmacokinetics (PK) and BA of MTX via the PJI in rats. PJI-injected India ink indicated penetration into the subcutis. The AUC

Indexed as

Antirheumatic AgentsDrug Delivery SystemsMethotrexateAdministration, OralAnimalsArthritis, RheumatoidBiological AvailabilityHumansInjections, JetInjections, SubcutaneousMaleRatsRats, Sprague-DawleyAntirheumatic AgentsMethotrexateBioavailabilityMethotrexateNeedle-free drug delivery systemPharmacokineticsPyro-drive jet injector

Identifiers

PMID41225020
PMCPMC12612075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.